EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Veradigm Inc. (MDRX) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Veradigm Inc. $13.31, price $4.81, upside +176.7%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US01988P1084

VI Veradigm Inc. logo Thin data Sep 23, 2026

Veradigm Inc.

MDRX · US

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value $13.31 · Strongly undervalued (+177%)
!Quality 59/100
!Weak Growth (revenue 5y −18.5 %/yr)
!Loss-making · -49.1% net margin (TTM)
✓Low debt · generates free cash flow
!Mixed vs. peers (6/12)
!Narrow moat 25/100
!Evidence only low, so the estimate is less certain
!Weak on future: 25 out of 100
Watch Veradigm Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$23.09 $3.90 Fair Value $13.31 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $3.90 – $23.09 · fair‑value band $10.37 – $17.05 · the $4.81 price screens below the $13.31 fair value. Dashed = 300-day average. As of Sep 23, 2026.

Follow Veradigm in your weekly email

Every Wednesday you see whether Veradigm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally.

Show more

Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising practice management software, AI patient scheduling software, and electronic statements and payments, and payerpath clearinghouse; revenue cycle services and coding services; electronic health records solutions, which include eprescribe with EPCS, EHR software, veradigm EHR, and practice fusion EHR; and patient engagement platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as veradigm connect, veradigm app expo, and diagnostic ordering and resulting network; life sciences, health plans and payers, and providers; and veradigm eprescribe enterprise. In addition, the company offers risk adjustment solutions, such as health equity analytics, risk adjustment analytics, risk mitigator, comprehensive submissions, and utilization analytics; quality analytics, risk adjustment, and quality management; clinical data exchange and coding solutions, including echart courier, echart coder, and echart integration and analytics; clinical data registries for physicians and veradigm payer insights; provider engagement solutions; care gap alerting, gap closure services, and veradigm payerpath solutions. Further, it provides real world data solutions, such as NLP-enriched EHR data solutions, and clinical data registries; real world evidence and real-world evidence analytics platform; and digital health media solutions. Additionally, the company serves physician practices, hospitals, laboratory and radiology centers, urgent care facilities, health IT companies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

Stock analysis

Veradigm Inc. (MDRX) currently trades at $4.81, while our model-based Fair Value estimate is $13.31, implying the stock looks roughly 63.9% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $12.34 per share, and 10 of the 10 models we run sit above the $4.81 price.

Bear case: the Asset-Based group reads lowest at $6.25, and 0 of the 10 models stay below the price. Evidence for this calculation is low.

Scenario range: $10.37 (bear) to $17.05 (bull), the price of $4.81 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

Veradigm Inc. reported revenue of $588M in FY2024 versus $1.6B in FY2019, a compound −18.5%/yr. Reported net income was −$86.5M in FY2024.

Key figures

Market cap $620M · P/S ratio 0.87 · EPS (TTM) $−2.70 · Net margin −14.7% · Return on equity −31.1% · Return on assets (EBIT) −1.0% · Operating margin 16.6% · Revenue (TTM) $594M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 7% below its 52-week high and 15% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at 177%, MDRX screens cheaper than that median.

Fair Value models

Bear $10.37 Fair Value $13.31 Bull $17.05
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $9.48 $12.09 $15.34 82
Growth DCF $9.60 $11.95 $14.75 80
5Y EBITDA Exit $9.63 $13.35 $17.50 76
All 10 models by family
DCF Models
FCF DCF $9.48 $12.09 $15.34 82
5Y Revenue Exit $9.07 $12.34 $16.36 73
5Y EBITDA Exit $9.63 $13.35 $17.50 76
10Y Revenue Exit $9.00 $11.79 $15.22 68
10Y EBITDA Exit $9.50 $12.42 $15.99 70
Multiples
EV/EBITDA $10.82 $13.67 $16.52 67
EV/Revenue $9.21 $12.19 $15.17 54
Asset-Based
NCAV (Graham) $4.67 $6.25 $9.34 54
Growth DCF
Growth DCF $9.60 $11.95 $14.75 80
Rev-Margin DCF $9.07 $12.44 $16.10 74

Open the full fair value analysis →

Notify me when MDRX reaches fair value

Put MDRX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 59/100

Of which business quality 59 · Market factors (momentum, volatility) 49

Profitability 12
Margins and returns on capital today
Quality Growth 33
Are margins and returns improving?
Cashflow 65
Earnings quality: real cash, not paper profit
Fin. Strength 79
Balance sheet, leverage, solvency risk
Investment 94
Disciplined investing over empire-building
Low Volatility 58
Calm price path (market factor)
Momentum 43
Price trend over the last 3–12 months (market factor)
52W Momentum 50
Distance to the 52-week high (market factor)
Net Issuance 90
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 21/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.5%
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6.1% (2019) → −4.6% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−4.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −6.9% a year for the price.

Watch MDRX, get fair value alerts →

Compare Veradigm Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 135 stocks

Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 59 · Above median
Fair Value upside +177% · Top 25%
Profitability
Return on assets −4% · Below median
Net margin (TTM) −49% · Bottom 25%
Operating margin (TTM) 17% · Top 25%
Growth and dividend
Revenue growth 5% · Below median
Balance sheet
Debt / equity 0.20× · Above median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 0.61× · Cheapest 25%
P/S (TTM) 1.04× · Cheaper than median
P/FCF 7.4× · Cheaper than median
PEG 2.42× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 6
FUTURE (revenue growth)25 · sector 34
PAST (return on equity)0 · sector 4
HEALTH (low debt)90 · sector 98
DIVIDEND (yield)0 · sector 46

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $260.91 $287.00 +10%
Pro Medicus Limited PME A$161.31 A$64.50 −60%
BrightSpring Health Services, Inc BTSG $56.55 $26.07 −54%
HealthEquity, Inc HQY $91.75 $100.93 +10%
Hinge Health, Inc HNGE $94.15 $51.66 −45%
10x Genomics, Inc TXG $80.70 $21.71 −73%
Waystar Holding WAY $25.63 $28.19 +10%
XtalPi Holdings 2228 HK$8.39 HK$1.50 −82%
Doximity, Inc DOCS $26.51 $31.41 +18%
Privia Health Group PRVA $19.46 $5.26 −73%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Veradigm Inc. · Fair Value
$13.31 +64%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Veradigm Inc. Fair Value". https://www.fairvalue-calculator.com/stock/MDRX

Frequently asked questions

Is Veradigm Inc. (MDRX) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $13.31 versus a price of $4.81, about +177% upside (undervalued).
What is the fair value of MDRX?
Our model-based fair value for Veradigm Inc. is $13.31 (as of Sep 23, 2026), built from audited fundamentals. The current price: $4.81.
What is the quality score of MDRX?
Veradigm Inc. has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Veradigm Inc. (MDRX)?
Our model-based price target is the fair value of $13.31 (as of Sep 23, 2026) from 10 valuation models. Cautious scenario $10.37, optimistic scenario $17.05. It is a calculation from audited fundamentals, not an analyst target.
What is the Veradigm Inc. stock forecast for 2026?
Our models put fair value at $13.31, about +177% upside versus a price of $4.81 (undervalued). Cautious scenario $10.37, optimistic scenario $17.05. The calculation is refreshed regularly with new filings.
What is the revenue of Veradigm Inc. (MDRX)?
Veradigm Inc. reported trailing-twelve-month revenue of about $594M (latest available figure, as of Sep 23, 2026).
What growth is priced into Veradigm Inc. (MDRX)?
For today's price to be fair in a discounted-cash-flow model, Veradigm Inc. would have to grow free cash flow by -4.7 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -18.5 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of MDRX use?
Our models discount Veradigm Inc. at 9.9 %: a base by market capitalisation (small), damped by beta 0.54, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Veradigm Inc. that is -4.7 % per year a year over ten years, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has Veradigm Inc. (MDRX) delivered so far?
Over the past 5 years revenue at Veradigm Inc. grew -18.5 % a year. The price currently implies -4.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Veradigm Inc. (MDRX) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Veradigm Inc. (-4.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Veradigm Inc. (MDRX)?
The free-cash-flow yield on the price is 13.43 %: that much free cash flow Veradigm Inc. produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Veradigm Inc. (MDRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Veradigm Inc. it is $13.31 per share (as of Sep 23, 2026), against a price of $4.81. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Veradigm Inc. stock overvalued or undervalued in 2026?
As of Sep 23, 2026, MDRX trades below its calculated fair value: price $4.81, fair value $13.31, a gap of about +177% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MDRX?
No. The price is what the market pays today ($4.81); the fair value is what the company's own numbers justify ($13.31). For Veradigm Inc. the two are $8.50 per share apart. That gap is exactly why we show both numbers side by side.
How much is Veradigm Inc. worth?
The market values Veradigm Inc. at about $620M (market capitalisation, as of Sep 23, 2026). Per share that is $4.81; our models calculate a fair value of $13.31 per share.
What do the bullish and bearish scenarios say about MDRX?
Our models span a range for Veradigm Inc.: cautious scenario $10.37, base $13.31, optimistic $17.05 per share (as of Sep 23, 2026, price $4.81). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of MDRX?
The PEG ratio of Veradigm Inc. is 2.42 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Veradigm Inc. (MDRX)?
Balance-sheet figures for Veradigm Inc. (as of Sep 23, 2026): return on equity −31.1%, debt of 0.20 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is MDRX from its 52-week high?
Veradigm Inc. trades at $4.81, about 7% below its 52-week high of $5.18 and 15% above the low of $4.20 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $13.31 is for.
Which stocks are comparable to Veradigm Inc.?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Veradigm Inc. stock attractive at the current price?
The data as of Sep 23, 2026: price $4.81, calculated fair value $13.31 (+177%), Quality Score 59/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MDRX calculated?
We run Veradigm Inc. through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $13.31, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Veradigm Inc. currently trades 177 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Veradigm Inc. (MDRX)?
The closing price on Sep 23, 2026 was $4.81. Our model-based fair value is $13.31, about +177% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Veradigm Inc. right now?
The price is below even our cautious bear case ($10.37). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (59/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Veradigm Inc.

How large is the market capitalisation of Veradigm Inc. (MDRX)?
The market capitalisation of Veradigm Inc. is $620M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Veradigm Inc. (MDRX)?
The price-to-sales ratio of Veradigm Inc. is 0.87 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Veradigm Inc. (MDRX)?
Earnings per share at Veradigm Inc. are $−2.70. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Veradigm Inc. (MDRX)?
The net margin of Veradigm Inc. is −14.7% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Veradigm Inc. (MDRX)?
The return on equity (ROE) of Veradigm Inc. is −31.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Veradigm Inc. (MDRX)?
On an EBIT basis the return on assets of Veradigm Inc. is −1.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Veradigm Inc. (MDRX)?
The operating margin of Veradigm Inc. is 16.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Veradigm Inc. (MDRX)?
Revenue at Veradigm Inc. is growing +5.0% versus a year earlier (3y avg −26.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Veradigm Inc. (MDRX)?
Earnings per share at Veradigm Inc. are growing −1.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Veradigm Inc. (MDRX) hold?
Veradigm Inc. holds more cash than debt, $227M net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Veradigm Inc. in the live analysis

One click puts Veradigm Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.